BenevolentAI becomes first AI company to appoint a Chief Medical Officer
BenevolentAI is the first AI company to have a CMO on its staff.
List view / Grid view
BenevolentAI is the first AI company to have a CMO on its staff.
The companies will work together on integrated drug discovery - medicinal and computational chemistry, biology and DMPK - to optimise Chronos’ selective orexin 1 antagonists that have shown promise in treating addiction.
Macrophage Pharma, a newly formed immune-oncology company, has successfully raised £9 million in a Series A equity financing round.
This award recognises outstanding achievements of female researchers in the life sciences in the past five years.
The monoclonal antibody biopharmaceutical group Kymab announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.
In this project, universities and companies across 11 European countries and the US will unite efforts to tailor the development and application of therapies to the individual MS patient.
The outlook for brain tumour patients is pretty negative, with the median survival rate for patients with glioblastoma multiforme, or GBM, a mere 14.2 months.
An team of scientists at the University of Nottingham has developed a technique to produce chemically functional spider silk that can be tailored to applications used in drug delivery, regenerative medicine and wound healing.
Medicinal marijuana is used frequently as a painkiller for a variety of ailments and diseases yet its psycho active side effects are seen by many as a significant disadvantage.
A new study led by scientists at the Scripps Research Institute (TSRI) sheds light on how the brain stores memories.
A new study by scientists at the University of Maryland School of Medicine have identified seven key proteins in the virus that may be the culprits behind its damaging effects.
Researchers at the University of Rochester Medical Centre have developed a new imaging technique to better assess eye health and potential disease.
The mechanical resistance of tumours and collateral damage of standard treatments often hinder efforts to defeat cancers.
Mission Therapeutics have appointed Dr Colin Goddard as non-executive Chairman, effective January 1st 2017.
A new study has confirmed the anti-diabetic properties of the purslane herb extract Portulaca oleracea L.